Biomedical Engineering Reference
In-Depth Information
Table 10.3
Published Clinical Studies on ALA- and MAL-PDT for Superfi cial Basal Cell Carcinoma (
Continued
)
MAL-PDT Study
Design
Incubation
Period (hr)
# Lesions Treated
(# Patients)
Light Source
(wavelength in nm)
Reference
Location
Response Rate
Follow-up (mo)
Vinciullo (149) (2005)
MAL-PDT “diffi cult
to treat” BCC
(Australian trial)
2× MAL-PDT
retreated after
3 mo if necessary
(lesion
preparation)
Face, scalp, neck,
trunk, and
extremities
3, Occluded
92 sBCC
Red light
(570-670 nm),
dose of 75 J/cm
2
,
light intensity of
50-200 mW/cm
2
93% CR at 3 mo,
82% at 24 mo
24
Surrenti (268) (2007)
2× MAL-PDT
(7 days apart)
with additional
monthly MAL-
PDT sessions up
to a maximum 8
where necessary
(lesion
preparation)
Face, neck, trunk,
and extremities
3, Occluded
94 (69)
Red LED light
source (634 ± 3
nm, 37 J/cm
2
, 50
mW/cm
2
)
89%CR 1 mo after
2 sessions, 2.4%
recurrence at
12 mo; no
additional clinical
benefi t beyond
2 MAL-PDT
sessions
12
Basset-Seguin (147)
(2008)
1× MAL-PDT vs.
double freeze-
thaw cryotherapy
retreated with
2× MAL-PDT
(7 days apart) or
double freeze-
thaw cryotherapy
after 3 mo if
necessary (lesion
preparation)
Face, scalp, neck,
trunk, and
extremities
3, Occluded
219 (114 treated
with MAL-PDT)
Red light
(570-670 nm),
dose of 75 J/cm
2
,
mean light
intensity of
150 mW/cm
2
MAL-PDT 97% at
3 mo vs.
cryotherapy 95%
60
Szeimies (148) (2008)
2× MAL-PDT
(7 days apart),
retreated after
3 mo if necessary
vs. surgery
Face, scalp, neck,
trunk, and
extremities
3, Occluded
246 (128 treated
with MAL-PDT)
Red LED light
source (634 ±
3 nm, 37 J/cm
2
,
50 mW/cm
2
)
MAL-PDT 92% at
3 mo vs. cryo-
therapy 99%;
9.3% recurrence
with MAL-PDT
vs. none with
surgery at 12 mo
12
Fantini (269) (2010)
1 or 2× MAL-PDT
(7 days apart), a
third PDT session
after 3 mo if
required (lesion
preparation)
Head, neck, trunk,
and limbs
3, Occluded
116
Red LED light
source (634 ±
3 nm, 37 J/cm
2
,
50 mW/cm
2
)
CR: 82%
Mean of 23.5
Abbreviations
: ALA, aminolevulinic acid; DMSO, dimethyl sulfoxide; EOD, every other day; LED, light-emitting diode; MAL, methyl aminolevulinic acid; Nd: YAG, neodymium-doped yttrium aluminum garnet;
PDT, photodynamic therapy; nBCC, nodular basal cell carcinoma; sBCC, superfi cial basal cell carcinoma; UV-A, ultraviolet-A.
